FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

Hepatology

Volumn 57, Issue 4, 2013, Pages 1407-1415

  Arao, Tokuzo ^a   Ueshima, Kazuomi ^a   Matsumoto, Kazuko ^a   Nagai, Tomoyuki ^a   Kimura, Hideharu ^a   Hagiwara, Satoru ^a   Sakurai, Toshiharu ^a   Haji, Seiji ^a   Kanazawa, Akishige ^b   Hidaka, Hisashi ^c   Iso, Yukihiro ^d   Kubota, Keiichi ^d   Shimada, Mitsuo ^e   Utsunomiya, Tohru ^e   Hirooka, Masashi ^f   Hiasa, Yoichi ^f   Toyoki, Yoshikazu ^g   Hakamada, Kenichi ^g   Yasui, Kohichiroh ^h   Kumada, Takashi ⁱ   Toyoda, Hidenori ⁱ   Sato, Shuichi ^j   Hisai, Hiroyuki ^k   Kuzuya, Teiji ^l   Tsuchiya, Kaoru ^l   Izumi, Namiki ^l   Arii, Shigeki ^m   Nishio, Kazuto ^a   Kudo, Masatoshi ^a   more..

^a KINKI UNIVERSITY   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c KITASATO UNIVERSITY HOSPITAL   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁱ OGAKI MUNICIPAL HOSPITAL   (Japan)

^j SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^k Japan Red Cross Date General Hospital   (Japan)

^l MUSASHINO RED CROSS HOSPITAL   (Japan)

^m TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FLUOROURACIL; GENOMIC DNA; INTERFERON; MESSENGER RNA; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER TISSUE; CHEMOSENSITIVITY; CHROMOSOME 11Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 84876107646     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25956     Document Type: Article

References (21)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. Ca Cancer J Clin 2005; 55: 10-30.
2. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 1219-1222.
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol 2008; 1: 18.
7. Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxyprothrombin after short-term treatment with sorafenib-a report of two cases. Case Rep Oncol 2010; 3: 298-303.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
10. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012; 14: 727-732.
11. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009; 69: 7160-7164.
12. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 2010; 70: 2053-2063.
13. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003; 78: 323-335.
14. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007; 13: 3051-3057.
15. Peters G, Brookes S, Smith R, Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 1983; 33: 369-377.
16. Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimizu K, et al. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci U S A 1986; 83: 3997-4001.
17. Takeo S, Arai H, Kusano N, Harada T, Furuya T, Kawauchi S, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 2001; 130: 127-132.
18. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-3110.
19. Chochi Y, Kawauchi S, Nakao M, Furuya T, Hashimoto K, Oga A, et al. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol 2009; 217: 677-684.
20. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32: 163-172.
21. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-420.